C07

Exploiting innate nucleic acid receptor pathways to enhance immunotherapy in SCLC

tba

Principal Investigator

Dr. med. Johannes Brägelmann SFB1399
Dr. med. Johannes Brägelmann

Junior Research Group Leader

Mildred Scheel School of Oncology

University Hospital Cologne & Department of TranslationalGenomics

University of Cologne

Curriculum Vitae (CV)

Project Interactions

A01

A05

A08

A09

B01

C01

C04

Z03

INF

Z05
Research Project Interaction
C07
SFB 1399 Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer

SFB 1399 Mechanisms of Drug Sensitivity
and Resistance in Small Cell Lung Cancer

c/o Department of Translational Genomics
University of Cologne
Weyertal 115b
50931 Cologne, Germany

+49-221-478-98777
info[@]sfb1399.de

Imprint
Privacy Policy

Partners:

University of Cologne University Hospital of Cologne University Hospital Essen Max Planck Institute for Metabolism Research TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Main University of Bonn University of Frankfurt Deutsche Forschungsgemeinschaft CIO Centrum für integrierte Onkologie Aachen Köln Bonn Düsseldorf Lung Cancer Group Cologne